Press coverage about Keryx Biopharmaceuticals (NASDAQ:KERX) has been trending somewhat positive on Sunday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Keryx Biopharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.8390337283177 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:

Shares of Keryx Biopharmaceuticals (KERX) traded up $0.21 during midday trading on Friday, reaching $4.49. The company’s stock had a trading volume of 2,557,975 shares, compared to its average volume of 1,337,928. The company has a debt-to-equity ratio of 13.95, a quick ratio of 3.76 and a current ratio of 4.46. Keryx Biopharmaceuticals has a one year low of $4.01 and a one year high of $8.38. The stock has a market capitalization of $535.32, a PE ratio of -3.12 and a beta of 2.71.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.08). The company had revenue of $18.70 million during the quarter, compared to analyst estimates of $17.53 million. Keryx Biopharmaceuticals had a negative net margin of 269.52% and a negative return on equity of 2,494.37%. The company’s revenue for the quarter was up 96.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.32) EPS. equities analysts predict that Keryx Biopharmaceuticals will post -0.59 EPS for the current year.

A number of equities research analysts have weighed in on the company. Stifel Nicolaus reduced their price objective on Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a research note on Wednesday, November 8th. Morgan Stanley reduced their price objective on Keryx Biopharmaceuticals from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday. Zacks Investment Research cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. Finally, ValuEngine cut Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $7.19.

In other news, COO Christine A. Carberry sold 9,048 shares of the business’s stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $4.87, for a total value of $44,063.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 16,561 shares of company stock worth $80,128. Corporate insiders own 2.58% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Keryx Biopharmaceuticals (KERX) Stock Price” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Insider Buying and Selling by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with's FREE daily email newsletter.